Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
Radium-223 for bone predominant metastatic castration resistant prostate cancer

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 792
Rating:

Dr Andrew Armstrong - Duke University School of Medicine, Durham, USA

Dr Armstrong speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about how he hypothesised that prostate cancer osteomimicry, a form of epithelial plasticity leading to an osteoblastic phenotype, may contribute to the intralesional deposition of radium-223 and subsequent irradiation of the tumour microenvironment.

He goes on to discuss a pharmacodynamic study that was conducted of radium-223 in men with bone predominant metastatic castration resistant prostate cancer to investigate genomic and phenotypic alterations in circulating tumour cells, ctDNA, and metastases. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation